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Clinical Severity Correlates with Impaired Barrier in
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Ikue Nemoto-Hasebe1, Masashi Akiyama1, Toshifumi Nomura1, Aileen Sandilands2, WH Irwin McLean2
and Hiroshi Shimizu1
Mutations in the gene-encoding filaggrin (FLG), a key molecule involved in skin barrier function, have been
shown to be a major predisposing factor for atopic dermatitis (AD; eczema). To elucidate the pathomechanisms
underlying filaggrin-related AD, we investigated stratum corneum (SC) hydration and transepidermal water loss
(TEWL) as parameters of barrier function in AD patients harboring FLG mutations compared to AD patients
without any FLG mutation. In filaggrin-related AD, SC hydration was both significantly reduced (Po0.01–0.05)
and thicker (Po0.01–0.05) than that in healthy controls. TEWL was demonstrably increased in non-filaggrin AD
compared to healthy controls (Po0.01–0.05). The objective score of atopic dermatitis (OSCORAD), a disease
clinical severity index, significantly correlated with TEWL (r¼ 0.81, Po0.005), SC hydration (r¼0.65, Po0.05),
and SC thickness (r¼ 0.59, Po0.05) in filaggrin-related AD. On the contrary, there was no correlation between
these parameters and the OSCORAD in non-filaggrin AD. Furthermore, a significant correlation was obtained
between the OSCORAD and specific IgE for house dust (r¼ 0.66, Po0.05), mite allergen (r¼ 0.53, Po0.05), and
cat dander (r¼ 0.64, Po0.05) in filaggrin-related AD, but not in non-filaggrin AD. All these data suggest that
experimentally demonstrable skin barrier defects due to FLG mutations may play a crucial role in the
pathogenesis of AD.
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INTRODUCTION
Atopic dermatitis (AD; also known as atopic eczema) is a
common skin disease that affects 15–20% of children in the
developed world (Roll et al., 2004). AD is thought to have a
variety of heterogeneous etiologic factors including genetic
predisposing factors and environmental factors. Recently,
mutations within the gene-coding filaggrin (FLG) were
reported to cause ichthyosis vulgaris (IV; Smith et al., 2006)
and to be a major genetic predisposing factor for AD (Palmer
et al., 2006; Sandilands et al., 2007). Filaggrin is essential for
the cell compaction process that precedes chemical cross-
linking in the biogenesis of the stratum corneum (SC).
Therefore, filaggrin is a key molecule in the initiation and
maintenance of skin barrier function. Profilaggrin is the main
protein component of the keratohyalin granules within the
last living cell layers of the epidermis (Irvine and McLean,
2006). In addition, the terminal degradation products of
filaggrin may act as a ‘‘natural moisturizing substance’’
(Rawlings and Harding, 2004). The fact that FLG mutations
have been reported as an important predisposing factor for
AD and secondary, less penetrant, atopic phenotypes such as
atopic asthma, suggests that the skin barrier defect is a
primary key event leading to allergic sensitization and
development of AD and related allergic phenotypes
(Weidinger et al., 2006).
FLG null mutations are found from 15 to 55% of AD
patients in European populations (Palmer et al., 2006;
Weidinger et al., 2006; Sandilands et al., 2007). Major
differences exist in the spectra of FLG mutations observed
between different ancestral groups. Specifically, FLG
ancestral mutations p.R501X and c.2282del4 in the
European population were not found in the Japanese
population (Nomura et al., 2007, 2008). However, very
recently, we identified four unique FLG mutations
p.Ser2554X, c.3321del, p.Ser2889X, and p.Ser3296X in
Japanese IV families and clarified that these four mutations
were found more than 24% of the Japanese AD patients
(Nomura et al., 2007, 2008).
Transepidermal water loss (TEWL) and SC hydration,
which are measurements of skin barrier function, were
reported to increase in AD patients due to their skin barrier
insufficiency (Aalto-Korte, 1995; Chamlin et al., 2002).
Significant correlations were observed between penetration
rates of a hydrophilic dye and elevated IgE levels in patients
with severe AD (Hata et al., 2002). In addition, percutaneous
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penetration of sodium lauryl sulphate was reported to be
increased in uninvolved skin of patients with AD (Jakasa
et al., 2006). Taken together, these findings strongly support
the hypothesis that patients with AD have a skin barrier
defect.
In this context, we hypothesized that, in filaggrin-related
AD, skin barrier defects caused by FLG deficiency is a
primary abnormality leading to the AD symptoms. In the
present study, to confirm this hypothesis, we evaluated skin
barrier function in two AD patient groups divided by
presence or absence of FLG mutations, by measurements of
TEWL, SC hydration, and thickness that are useful markers of
skin barrier function (Holm et al., 2006).
RESULTS
Significant decrease of hydration and increase of TEWL in AD
We have summarized the details of clinical information from
the patients and included FLG mutations (Table S1) and data
on clinical severity as the objective score of atopic dermatitis
(OSCORAD), SC hydration, TEWL, and SC thickness and in
three representative regions (both the flexor and extensor
aspects of the forearm, as well as the back; Table 1 and
Figure 1). Scores for regions in each AD patient are shown in
Table S2. SC hydration in AD patients was decreased in all
the three regions of the body, as shown in Table 1 and
Figure 1.
There were significant differences in SC hydration
between filaggrin-related AD and normal controls on the
back (Po0.01) and on the extensor aspect of the forearm
(Po0.05), and to a lesser extent between non-filaggrin AD
and normal control skin on the extensor aspect of the forearm
(Po0.05). Average SC hydration values from the three
regions were reduced in filaggrin-related AD patients
compared with normal controls (Po0.01).
Transepidermal water loss values in each group are
summarized in Table 1 and Figure 1. TEWL in non-filaggrin
AD patients was significantly increased compared with that
in normal controls on the extensor aspect of the forearm, on
the back and the average of the three regions (Po0.01) and
slightly reduced on the flexor aspect of the forearm (Po0.05).
There was a significant TEWL increase in non-filaggrin AD
patients compared with filaggrin-related AD individuals on
the extensor aspect of the forearms (Po0.05), on the back
(Po0.05), and for the average TEWL in the three regions
(Po0.05).
It was statistically confirmed that SC hydration was
significantly lower and that the TEWL was significantly
higher in the filaggrin-related AD compared to those of the
non-filaggrin AD by using the Wilcoxon rank sum test and
Turkey–Kramer’s honestly significant difference test.
SC thickness was significantly increased in filaggrin-related AD
compared with that in non-filaggrin AD
Stratum corneum thickness in normal controls, filaggrin-
related AD, and non-filaggrin AD is summarized in Table 1
and Figure 1.
Stratum corneum thickness in filaggrin-related AD was
significantly increased compared to that of normal controls
on the flexor aspect of the forearm (Po0.05), on the extensor
aspect of the forearm (Po0.01), and on the back (Po0.05).
Interestingly, there was a significant increase in SC thickness
from filaggrin-related AD individuals compared with back
skin from non-filaggrin AD patients (Po0.05). Average SC
thickness was remarkably increased in filaggrin-related AD
compared with normal controls (Po0.01) and compared to
non-filaggrin AD patients (Po0.05).
Increased SC thickness in filaggrin-related AD was verified
by conventional histology, as follows. SC thickness measured
Table 1. Summary of the patients’ SC hydration, TEWL, and SC thickness
Group Flexor aspect of the forearm Extensor aspect of the forearm Back Average of the three regions
SC hydration (ms) (95% confidence interval)
Filaggrin-related AD 7.67±5.98 (3.87–11.46) 6.28±5.00* (3.10–9.46) 9.46±6.63** (5.25–13.67) 7.80±5.17** (4.51–11.09)
Non-filaggrin AD 9.93±5.61 (6.37–13.49) 7.39±6.30* (3.38–11.39) 14.65±8.88 (9.01–20.29) 10.66±5.11 (7.41–13.91)
Control 11.84±6.40 (7.78–15.91) 12.71±4.48 (9.86–15.56) 20.40±7.43 (15.68–25.12) 14.99±5.06 (11.77–18.20)
TEWL (gm2 per hour) (95% confidence interval)
Filaggrin-related AD 14.20±5.58 (10.65–17.75) 11.05±3.70# (8.70–13.39) 12.68±6.49# (8.55–16.80) 12.64±3.90# (10.17–15.12)
Non-filaggrin AD 20.44±19.29* (8.18–32.69) 19.94±11.98** (12.32–27.55) 20.87±11.57** (13.52–28.22) 20.42±12.51** (12.47–28.37)
Control 7.07±2.45 (5.51–8.62) 6.40±1.77 (5.27–7.52) 6.84±1.47 (5.91–7.78) 6.77±1.74 (5.67–7.87)
SC thickness (mm) (95% confidence interval)
Filaggrin-related AD 57.74±34.90* (35.56–79.92) 72.87±50.27** (40.93–104.81) 62.24±55.61*,# (26.91–97.57) 64.28±42.28** (37.42–91.15)
Non-filaggrin AD 40.92±32.88 (20.03–61.81) 42.92±19.63 (30.45–55.39) 26.14±15.31 (16.41–35.87) 36.66±18.30 (25.03–48.29)
Control 28.09±12.55 (20.11–36.06) 22.73±10.10 (16.31–29.15) 20.45±7.59 (15.63–25.27) 23.76±8.88 (18.11–29.40)
Abbreviations: AD, atopic dermatitis; SC, stratum corneum; TEWL, transepidermal water loss.
*Po0.05, **Po0.01 vs Control #Po0.05 vs non-filaggrin AD (Tukey–Kramer’s honestly significant difference test).
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in conventional histological slides was 42.8 mm in patient 3
(filaggrin-related AD), 23.8 mm in patient 21 (non-filaggrin
AD), and 14.2mm in patient 27 (IV without concomitant AD;
Figure 2). SC thickness as measured by the corneometer was
47.6 mm in patient 3 (filaggrin-related AD), 25.3mm in patient
21 (non-filaggrin AD), and 14.7mm in patient 27 (IV without
concomitant AD). These results confirmed that SC thickness
data obtained using the corneometer are reliable and reflect
the true SC thickness. Using hematoxylin and eosin-stained
sections from patient 3 (filaggrin-related AD), additional
layers of corneocytes in the SC were seen. Thus, the increase
in SC thickness in filaggrin-related AD seems to be due to
increased layers of corneocytes.
AD clinical severity was correlated with SC barrier defects
indicated by TEWL and SC hydration in filaggrin-related AD,
but not in non-filaggrin AD
There was no significant difference in AD severity as
indicated by OSCORAD between filaggrin-related AD and
those of non-filaggrin AD using the Wilcoxon rank sum test
and box-whisker plots; OSCORAD (interquartile range or
interquartile interval: filaggrin-related AD, 14.71–31.93; non-
filaggrin AD, 26.88–35.75; Figure S1).
In filaggrin-related AD, negative correlation was con-
firmed by simple regression analysis between the clinical AD
severity indicated with OSCORAD and average SC hydration
on all the three examined sites (correlation coefficient
r¼0.65, Po0.05; Figure 3). Simple regression analysis
revealed a significant, positive correlation between the
OSCORAD and average TEWL on all the three examined
sites (correlation coefficient r¼0.81, Po0.005) and between
the OSCORAD and average SC thickness (correlation
coefficient r¼ 0.59, Po0.05; Figure 3).
In non-filaggrin AD, simple regression analysis revealed
that there was no significant correlation between the
OSCORAD and average TEWL (correlation coefficient
r¼ 0.01, P40.5), between the OSCORAD and average SC
hydration (correlation coefficient r¼0.21, P40.5), or
between the OSCORAD and SC thickness (correlation
coefficient r¼0.05, P40.5; Figure 3).
Significant correlation was obtained between the OSCORAD
and specific IgE for house dust, mite allergen, and cat dander in
filaggrin-related AD
We have shown the clinical history including the duration of
AD, presence, or absence of AD family history, complication
of asthma, rhinitis, and seasonal changes of disease activity,
and laboratory data including peripheral blood eosinophil
count (EOS), lactate dehydrogenase (LDH), total serum IgE,
and allergen-specific IgE tests (IgE-multiple antigen simulta-
neous test (MAST), Table S1).
Atopic dermatitis family history was frequently observed in
both AD patient groups (filaggrin-related AD, 10/12; non-
filaggrin AD, 7/12). As complications, asthma (filaggrin-
related AD, 5/12; non-filaggrin AD, 6/12), and rhinitis
(filaggrin-related AD, 7/12; non-filaggrin AD, 9/12) were
frequently seen. Patients whose skin lesions tended to get
worse in winter were 3/12 in filaggrin-related AD and 2/12 in
non-filaggrin AD. Patients whose skin lesions tend to get
worse in summer were 0/12 in filaggrin-related AD and 4/12
in non-filaggrin AD. Due to the limited number of patients, it
is difficult to draw firm conclusions about the clinical features
including complications, family history, and seasonal
changes in disease severity.
The IgE-MAST score of both AD groups showed
high average, including IgE-MAST against house dust
(filaggrin-related AD, 16.01; non-filaggrin AD, 24.00), mite
(filaggrin-related AD, 63.41; non-filaggrin AD, 66.00),
grass pollen (filaggrin-related AD, 23.46; non-filaggrin AD,
20.35), cedar pollen (filaggrin-related AD, 10.41; non-
filaggrin AD, 11.66), fungal allergen (filaggrin-related AD,
6.33; non-filaggrin AD, 9.52), canine dander (filaggrin-
related AD, 18.86; non-filaggrin AD, 37.07), feline dander
(filaggrin-related AD, 29.64; non-filaggrin AD, 34.38), egg
albumen (filaggrin-related AD, 4.21; non-filaggrin AD, 6.80),
milk (filaggrin-related AD, 2.92; non-filaggrin AD, 2.32),
wheat (filaggrin-related AD, 2.06; non-filaggrin AD, 2.30),
and soy beans (filaggrin-related AD, 5.12; non-filaggrin AD,
2.90). No significant difference was seen in IgE-MAST
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Figure 1. SC hydration, TEWL, and SC thickness on the flexor and extensor
aspects of the forearm, on the back and average of the three regions. (Top)
Comparison of SC hydration (ms) between filaggrin-related AD, non-filaggrin
AD and the control group. (Middle) Comparison of TEWL (gm2 per hour)
between filaggrin-related AD, non-filaggrin AD and the control group.
(Bottom) Comparison of SC thickness (mm) between filaggrin-related AD,
non-filaggrin AD and the control group. Data with P-values *Po0.05 were
evaluated as significant and **Po0.01 were evaluated as highly significant.
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scores for any antigen between filaggrin-related AD and non-
filaggrin AD.
Neither EOS, total serum IgE nor serum LDH showed any
apparent association with the OSCORAD in either filaggrin-
related AD or non-filaggrin AD by Wilcoxon rank sum test.
Although no significant correlation was obtained between
EOS, total serum IgE, LDH, and the OSCORAD in either
filaggrin-related AD or in non-filaggrin AD by simple
regression test, the OSCORAD and specific IgE for several
allergens in filaggrin-related AD revealed a significant
correlation coefficient, such as between OSCORAD
and IgE for house dust (correlation coefficient r¼0.66,
Po0.05) in filaggrin-related AD, between the OSCORAD
and IgE for mite allergen (correlation coefficient r¼0.53,
Po0.05) in filaggrin-related AD, and between the OSCOR-
AD and IgE for cat dander (correlation coefficient r¼0.64,
Po0.05) in filaggrin-related AD. IgE for the other allergens in
filaggrin-related AD did not show any correlation with the
OSCORAD. IgE MAST scores for none of the allergens
exhibited any correlations with the OSCORAD in non-
filaggrin AD.
DISCUSSION
Atopic dermatitis is thought to comprise a group of patients
with heterogeneous pathogenic factors. For a long time,
abnormalities in the immune system have been highlighted as
causative factors underlying AD. Recently, FLG mutations
were found to be an important predisposing factor for AD and
epidermal barrier defects have been attracting attention as an
important pathomechanisms leading to AD.
The epidermal barrier function, in ichthyosis patients
measured by SC hydration, thickness, and TEWL are known
to be associated with the severity of the disease (Tomita
et al., 2005). Additionally, in AD patients, TEWL was
reported to be increased, although controversy still remains
as to whether the defective barrier function in AD patients
is a primary cause of AD or a secondary consequence
following dermatitis (Leung, 2000). Several studies have
proven that there is a close correlation between clinical
severity assessed using the SCORAD and skin barrier
dysfunction in AD patients (Chamlin et al., 2002; Sugarman
et al., 2003).
Stratum corneum hydration was marginally lower in
filaggrin-related AD compared to non-filaggrin AD, although
no statistical significance was obtained between our two AD
groups. In contrast, TEWL was higher in non-filaggrin AD
compared to in filaggrin-related AD. Low SC hydration in
filaggrin-related AD might be indirectly related to barrier
defects, but could primarily be related to a deficiency of
water-binding filaggrin breakdown products (natural moistur-
izing factor) within the SC of filaggrin-related AD patients.
From the results of the present study, SC thickness was
significantly thicker in filaggrin-related AD than in non-
filaggrin AD. In contrast, the TEWL increase observed in
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Figure 2. SC thickness measured by conventional histological methods and filaggrin immunostaining. Note remarkably increased SC thickness in filaggrin-
related AD (a) due to an increased number of cornified cell layers. Immunohistochemical staining with anti-filaggrin monoclonal antibody against an epitope
conserved in all filaggrin repeat peptides revealed a marked reduction of filaggrin staining in the epidermis of filaggrin-related AD (e) and IV without
concomitant AD (g). (a–d) Hematoxylin and eosin staining; (e–h) filaggrin immunostaining. (a, e) Patient number 3 with compound heterozygous FLG mutations,
c.3321delA, and p.Ser2554X (filaggrin-related AD); (b, f) patient number 21 without any FLG mutation (non-filaggrin AD); (c, g) patient number 27, IV without
concomitant AD, harboring heterozygous FLG mutation p.Ser2554X; (d, h) normal control. Bars, 25 mm.
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non-filaggrin AD was significantly greater than that in
filaggrin-related AD. It appears interesting that there seems
to be a clear difference in barrier formation (SC thickness) and
function (TEWL) between the two groups. In total, 4 patients
out of 12 in filaggrin-related AD exhibited concomitant IV,
although none of non-filaggrin AD patients had concomitant
IV. Thus, we cannot exclude the possibility that remarkable
SC thickness in filaggrin-related AD is related to the IV
characteristics of patients, though SC was generally thinner in
IV patients without AD in the present study. In addition, in
our study, a negative correlation between the clinical AD
severity (OSCORAD) and SC hydration and a positive
correlation between the OSCORAD and TEWL were con-
firmed only in filaggrin-related AD. There was no significant
correlation between the OSCORAD and SC hydration and
between the OSCORAD and TEWL in non-filaggrin AD.
However, according to a previous report studying French AD
patients (Hubiche et al., 2007), no significant difference was
observed in the level of barrier function defects between
filaggrin-related AD and non-filaggrin AD. It should be noted
that in the previous study (Hubiche et al., 2007), that the AD
cohort was screened only for the two common filaggrin
mutations, p.R501X, and c.2282del4 and was not screened
for the many newly identified European filaggrin mutations,
some of which are also prevalent in European populations
(Sandilands et al., 2007).
The OSCORAD scoring in the present study showed slight
skewing between the two AD groups. Filaggrin-related AD
seemed in general to have a relatively low OSCORAD score.
This fact could have affected the interpretation of the other
data. The effect of omitting treatments for 24 hours might also
make non-filaggrin AD patient’s disease worse than that of
filaggrin-related AD patients. Thus, we checked this skewing
using the Wilcoxon rank sum test and box-whisker plots,
whereby the skewing was in fact revealed to be nonsignifi-
cant (Figure S1). No clinically relevant differences were seen
between filaggrin-related AD and non-filaggrin AD in the
present study.
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Figure 3. Correlation of clinical severity (OSCORAD) and SC hydration (average values of the three regions, ls), OSCORAD and TEWL (average values of the
three regions, gm2 per hour), and OSCORAD and SC thickness (average values of the three regions, lm). (a) Filaggrin-related AD. A significant correlation
was shown between OSCORAD and each parameter. Data with P-values *Po0.05 were evaluated as significant and **Po0.005 were evaluated as highly
significant. (b) Non-filaggrin AD. No statistically significant correlation was shown between OSCORAD and any parameter.
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From our results, increased SC thickness, TEWL, and
reduced SC hydration are thought to be good indicators to
evaluate the severity of filaggrin-related AD. Furthermore, in
filaggrin-related AD, increased SC thickness and TEWL and
reduced SC hydration might be useful to predict clinical
course of the patients. In addition, given the strong
correlations between the AD severity score (OSCORAD)
and all the three parameters of skin barrier (TEWL, SC
hydration, and thickness) obtained only in filaggrin-related
AD, we are able to speculate that epidermal barrier
defects may be one of the primary abnormalities in
filaggrin-related AD.
Only in filaggrin-related AD, significant positive correla-
tions were confirmed between the OSCORAD and IgE for
house dust, between the OSCORAD and IgE for mite
allergen, and between the OSCORAD and IgE for cat
dander. There was no significant correlation between the
OSCORAD and allergen-specific IgE in non-filaggrin AD.
These results indicated the possibility of percutaneous
sensitization for the allergens due to skin barrier defects in
filaggrin-related AD. Mechanisms by which barrier defects
due to FLG mutations contribute to the overall clinical end
points of AD have yet to be completely clarified. Profilaggrin/
filaggrin is crucial for maintaining the epidermal barrier
function (Hudson, 2006). FLGmutations result in complete or
incomplete loss of profilaggrin/filaggrin peptides and seem to
be important in facilitation of allergic sensitization in AD
patients. Defective epidermal barrier function provides
easy access of allergens, antigens, and irritants through
the epidermis, leading to stimulation of active T cells
that contribute to more inflammation of the skin (Leung
et al., 1995).
We examined the histopathological features of three
patients, one filaggrin-related AD, one non-filaggrin AD,
and one IV without concomitant AD. Our results demonstrate
that SC thickness measured in conventional histological
slides correlated well to SC thickness as measured by a
corneometer. Concordance of SC thickness measured by a
corneometer and that measured by conventional histological
methods was previously reported in ichthyosis patients
(Tomita et al., 2005). Thus, we feel that SC thickness
measured by a corneometer without any further invasive
procedures may be a useful and reliable parameter of
hyperkeratosis. From histopathological observations, the
thickening of SC in filaggrin-related AD (patient 3) appeared
to be due to an increased number of cornified cell layers in
SC. This observation suggests that hyperkeratosis in filaggrin-
related AD might be caused by reduced desquamation of
cornified cells, but not by diminished compaction of the
corneocytes in the SC. These observations further emphasize
the close pathophysiological relationship between ichthyosis
vulgaris and filaggrin-related AD.
In our study, AD patients showing aggravation in summer
were restricted to the AD group of the patients without FLG
mutations, although the number of patients included in the
present study was limited. Overexposure to sweat antigens
was suggested to be an accelerating factor for AD eczema
(Tanaka et al., 2006). AD patients with summer aggravation
might have other predisposing factors including sweat
antigen exposure, but not epidermal barrier defects. Further
study with a larger number of patients is needed to verify this
hypothesis.
Our results showed remarkable barrier dysfunction (in-
creased TEWL) in AD patients who did not have any FLG
mutations. Jakasa et al. (2007) reported altered penetration of
polyethylene glycols into uninvolved AD patient skin. There
are likely a variety of mechanisms that modulate barrier
integrity, other than the profilaggrin/filaggrin system,
although it should be noted that there may be other filaggrin
mutations still remain undetected in the Japanese population.
Other structural molecules may also contribute to skin barrier
formation by as yet unknown mechanisms.
MATERIALS AND METHODS
Patients
We selected 24 patients with AD according to criteria proposed by
Hannifin and Rajka (1980), 14 males and 10 females, with a mean
age of 21.36 years (range, 6–33 years). Twelve patients harbored FLG
mutations (filaggrin-related AD) and the other twelve patients had no
apparent FLG mutation (non-filaggrin AD). They were all treated by
topical steroid ointment ranged from moderate to very strong, topical
tacrolimus, moisturizer (heparinoid), or oral anti-histamines. We
interviewed patients about disease duration of AD, presence or
absence of family history of AD, and other atopic disorders including
asthma or allergic rhinitis, and seasonal difference in AD severity.
Patient numbers 3, 4, 10, and 11 had features of concomitant IV
including hyperlinearity in the palms and scales on the lower legs.
Patient numbers 1, 2, 5, 6, 7, 8, 9, 12, and 13–24 had dry skin, but no
apparent concomitant IV features. In addition, three typical IV
patients without concomitant AD harboring FLG mutations were
included in the present study.
Age-matched healthy volunteers were included in the present
study as controls. The control group consisted of 12 healthy
individuals aged 6–30 years (eight male and four female) without
any past or present skin disease.
The present study was approved by the Institutional Ethical
Committee of Hokkaido University Graduate School of Medicine.
This study was conducted according to all the Declaration of
Helsinki Principles. Participants or their legal guardians gave their
written informed consent.
Filaggrin genotyping
FLG mutation analysis was performed in patients and their family
members. Briefly, genomic DNA isolated from peripheral blood was
subjected to PCR amplification, followed by direct automated
sequencing using ABI PRISM 3100 or 3730 genetic analyzers
(Applied Biosystems, Foster City, CA). Mutations p.Ser2554X,
p.Ser2889X, and p.Ser3296X were screened using restriction
enzyme digestion of PCR products (Nomura et al., 2007, 2008).
Mutation c.3321del was screened by fluorescent PCR (Nomura
et al., 2007). Primers and PCR conditions were as described
previously (Nomura et al., 2007, 2008).
Disease severity
The SCORAD (severity scoring of AD, score range 0–103; European
Task Force on Atopic Dermatitis, 1993) utilizes the rule of nines with
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six clinical features of AD disease intensity: erythema/darkening,
edema/papulation, oozing/crust, excoriations, lichenification/prur-
igo, and dryness. Dryness was evaluated on noninflamed skin. The
other features were assessed on a representative area for a given
intensity item, also on a scale of 0–3. To measure AD clinical
severity, we employed the objective SCORAD (OSCORAD; score
range 0–83; Holm et al., 2006). In the OSCORAD, which is often
used in clinical trials, two subjective symptoms (itch and sleep loss)
were excluded from the conventional SCORAD.
Measurement of stratum corneum hydration, TEWL, and
stratum corneum thickness
Measurements were performed under standardized conditions, that
is, at a room temperature of 22–25 1C and a humidity level of
40–55%. Before the measurements, patients were given time to adapt
to room conditions without covering the measurement sites with
clothes. All the measurements were performed by one investigator
(INH). Almost all patients were taking anti-histamines, and treated by
topical steroids, topical immunosuppressants, emollients (hepari-
noid), which were all kept maintained. However, from 2100 hours
on the day before the investigation, nothing was applied to the skin
to be examined. To exclude the bias of different dermatitis severities
in the examination sites, three body sites, clinically normal areas in
the extensor and flexor aspects of the forearm and on the back, were
selected for examination. All measured values were expressed as the
median of three recordings to avoid measuring inaccuracies. SC
hydration was measured as (low-frequency susceptance) (square
root of electrode distance)/(square root of low frequency conduc-
tance) by using noninvasive methods (Yamamoto, 1994) with a
Corneometer ASA-M2 (ASAHI BIOMED, Yokohama, Japan). ASA-
M2 evaluated conductance of two different electric currents with
low frequency and high frequency. The low-frequency current was
limited to the superficial SC and the high-frequency current
penetrated the highly moist region immediately below the SC. Thus,
SC thickness was calculated from low-frequency susceptance and
high-frequency admittance by the corneometer as (square root of
low-frequency susceptance)/(high-frequency admittance; Yamamo-
to, 1994). TEWL was measured using Evaporimeter AS-TW1 (ASAHI
BIOMED, Yokohama, Japan). AS-TW1 utilizes the ventilated
chamber method of measuring TEWL. Its hygrometer measures the
humidity of incoming air and of outgoing air that has passed over the
test area of skin, and TEWL is calculated from the difference. TEWL
measurements were done on the extensor and flexor sides of the
forearm that were observed clinically normal. All the measurements
were performed three times for each skin spot.
Immunohistochemical staining
Immunoperoxidase staining of paraffin-embedded sections was
performed using the ChemMate Peroxidase/DAB system (Dako
Cytomation, Hamburg, Germany). Mouse monoclonal antibody
15C10 (Novocastra, Newcastle, UK) was used to detect the human
filaggrin repeat unit. Antigen retrieval was performed by heating
sections under pressure for 10 to 15minutes in 10 nmol l1 citrate
buffer, pH 6.0.
Laboratory tests
Peripheral blood EOS count (number 100 per ml; normal 40–440),
serum LDH (IU l1; normal 119–229), total serum IgE (IUml1;
normal 0.0–400.0), and allergen-specific IgE (SRL Inc., Tokyo,
Japan) were measured. Allergen-specific IgE were estimated by
fluoroenzyme immunoassays for house dust, mite allergen, grass
pollen (Tancy), cedar pollen, fungal allergen (Candida), animal
dander, and foods. Concerning to the sensitivity for detection of
specific IgE, 100 lumicount and values greater than or equal to 100
lumicount were considered positive (þ ).
Statistical analysis
Statistical analysis was performed using Excel 2000 (Microsoft,
Redmond, WA) with the add-in software Statcel 2 (OMS, Saitama,
Japan) and JMP 6.0.3 (SAS Institute, Tokyo, Japan). Wilcoxon rank
sum and Turkey–Kramer’s honestly significant difference tests were
used to compare the continuous variables between the group of total
AD patients and normal controls, and between filaggrin-related AD
and non-filaggrin AD. Data with P-values less than 0.05 were
evaluated as significant. We interpreted P-values less than 0.01 as
highly significant.
Simple regression analyses were also used to identify significant
associations of SC hydration, thickness, or TEWL to OSCORAD.
Data with P-values less than 0.05 were evaluated as significant. We
interpreted P-values less than 0.005 as highly significant. Wilcoxon
rank sum test and simple regression analyses were performed to
assess the association or correlation between different biological
markers including IgE, LDH, EOS, and the OSCORAD.
CONFLICT OF INTEREST
Irwin McLean has filed patents relating to genetic testing and therapy
development aimed at the filaggrin gene.
ACKNOWLEDGMENTS
We thank Dr James R. McMillan for his critical reading of this paper. We
thank Ms Akari Nagasaki, for her fine technical assistance on this project.
Filaggrin/ichthyosis/eczema research in the McLean laboratory is supported
by grants from the British Skin Foundation, National Eczema Society (UK),
and the UK Medical Research Council (reference number G0700314) and
donations from anonymous families affected by eczema in the Tayside Region
of Scotland. This work was supported in part by Grants-in-Aid from the
Ministry of Education, Science, Sports, and Culture of Japan to M. Akiyama
(Kiban B 18390310 and Kiban B 20390304).
SUPPLEMENTARY MATERIAL
Table S1. Clinical information on the patients and FLG mutations.
Table S2. Patients’ clinical severity (OSCORAD), SC hydration, TEWL, and
SC thickness.
Figure S1. Box-whisker plots of OSCORAD in the two AD groups. Wilcoxon
rank sum test and box-whisker plots revealed no significant difference in
OSCORAD scores between filaggrin-related AD and non-filaggrin AD.
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